Eupraxia Pharmaceuticals Inc. (TSX:EPRX)

Canada flag Canada · Delayed Price · Currency is CAD
7.32
-0.14 (-1.88%)
Aug 1, 2025, 3:59 PM EDT
-1.88%
Market Cap262.42M
Revenue (ttm)n/a
Net Income (ttm)-39.19M
Shares Out35.85M
EPS (ttm)-1.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,251
Average Volume23,909
Open7.31
Previous Close7.46
Day's Range7.17 - 7.38
52-Week Range3.07 - 8.13
Beta1.55
RSI53.61
Earnings DateAug 8, 2025

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 33
Stock Exchange Toronto Stock Exchange
Ticker Symbol EPRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.